Showing results (131-140 of 185) with videos related to

Sort By:
Pageof 19
Leukemia|August 27, 2011
Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysisK Ishiyama, A Takami, Y Kanda, et al.
Bone Marrow Transplantation|May 25, 2004
Allogeneic myeloablative transplantation for patients aged 50 years and overM Yanada, N Emi, T Naoe, et al.
International Journal of Hematology|October 1, 1996
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study GroupY Kagami, Y Ariyoshi, A Horiuchi, et al.
Journal of Thrombosis and Haemostasis : JTH|January 18, 2006
Fatal thrombosis of antithrombin-deficient mice is rescued differently in the heart and liver by intercrossing with low tissue factor miceM Hayashi, T Matsushita, N Mackman, et al.
Blood|August 1, 1997
Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acidT Tobita, A Takeshita, K Kitamura, et al.
Journal of Pediatric Hematology/Oncology|June 17, 1998
Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemiaY Takahashi, K Horibe, H Kiyoi, et al.
Leukemia|February 13, 2009
GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell linesA Furuhata, M Murakami, H Ito, et al.
Bone Marrow Transplantation|May 24, 2005
Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosisK Shimada, T Yokozawa, Y Atsuta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2011
A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignanciesS Terakura, Y Atsuta, M Sawa, et al.
Leukemia|April 17, 2009
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cellsA Takeshita, N Yamakage, K Shinjo, et al.
Pageof 19